A study published Monday in JAMA examined the growth of patents on small‑molecule drugs approved by the U.S. Food and Drug Administration (FDA). The researchers documented a sharp rise in the number of patents per drug, driven largely by non‑primary patents that do not cover the active ingredient. Those overlapping patents form “patent thickets” that postpone generic competition and sustain high drug prices.
Key Takeaways
- S. Sean Tu, a drug‑and‑patent law scholar at the University of Alabama, led the research.
- The patent analysis covered FDA‑approved small‑molecule drugs from 1990 through 2019.
- The authors argue that the rapid expansion of non‑primary patents may curb price competition, letting brand‑name firms maintain monopoly pricing.
| Metric | Value | Why it matters |
|---|---|---|
| Publication venue | JAMA | Peer‑reviewed platform adds credibility to the findings. |
| Data source | FDA drug‑approval records | Ensures the analysis reflects officially sanctioned medicines. |
| Study period | 1990‑2019 | Captures three decades of patent‑filing behavior. |
Scope and Methodology of the Research
The team, headed by S. Sean Tu, extracted every small‑molecule drug that received FDA approval between 1990 and 2019. For each product they counted all associated patents, distinguishing “primary” claims that protect the active ingredient from “non‑primary” claims covering formulation, dosing regimens, manufacturing processes, and other peripheral aspects. By aggregating these counts, the authors could trace how the patent landscape evolved over thirty years.
Why Non‑Primary Patents Are Multiplying
While primary patents protect the core chemical entity, non‑primary patents have proliferated as companies seek additional layers of protection. The study shows that the average number of patents per drug has risen sharply, with non‑primary filings accounting for the bulk of the increase. This strategy, often termed “evergreening,” extends market exclusivity without delivering new therapeutic value.
Patent Thickets and Their Effect on Generic Entry
When a single drug is encircled by dozens of overlapping patents, generic manufacturers must navigate a complex web of legal hurdles. Each non‑primary patent can trigger separate infringement lawsuits, inflating litigation costs and delaying the launch of lower‑cost alternatives. The result is a “patent thicket” that effectively blocks competition even after the primary patent expires.
Implications for Drug Pricing and Patient Costs
By sustaining monopoly pricing, these thickets keep drug prices elevated for patients and health‑care systems. The authors contend that the surge in non‑primary patents limits price competition, allowing brand‑name firms to maintain high profit margins without introducing clinically superior products. Consequently, the financial burden on patients rises, and overall health
Reporting based on: original source.
Comments
Post a Comment